Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Prostate Cancer

Free Subscription 03.05.2021 1 AJR Am J Roentgenol 5 BJU Int 1 BMC Cancer 1 BMC Urol 1 Br J Radiol 1 Cancer 1 Cancer Res 1 Clin Cancer Res 1 Int J Radiat Oncol Biol Phys 2 Int J Urol 2 J Clin Oncol 4 J Nucl Med 5 J Urol 1 Magn Reson Imaging 1 PLoS One 6 Prostate 3 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. DENIFFEL D, Haider MA
   Beyond the AJR: "Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study".
   AJR Am J Roentgenol. 2021 Apr 28. doi: 10.2214/AJR.21.26048.
   PubMed        
   
   

   
   BJU Int

2. 
   Recent advances in the diagnosis and management of prostate cancer.
   BJU Int. 2021;127:518-519.
   PubMed        
   
   
3. AHO T, Al-Hayek S, Winterbottom A, Koo B, et al
   'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
   BJU Int. 2021;127:37-40.
   PubMed        
   
   
4. 
   World News.
   BJU Int. 2021;127:1-3.
   PubMed        
   
   
5. HUANG MM, Su ZT, Becker REN, Pavlovich CP, et al
   Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial.
   BJU Int. 2021;127:190-197.
   PubMed         Abstract available
   
   
6. COVAS MOSCHOVAS M, Bhat S, Onol F, Rogers T, et al
   Early outcomes of single-port robot-assisted radical prostatectomy: lessons learned from the learning-curve experience.
   BJU Int. 2021;127:114-121.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. LEE J, Yang SW, Jin L, Lee CL, et al
   Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
   BMC Cancer. 2021;21:472.
   PubMed         Abstract available
   
   

   
   BMC Urol

8. CHEN Y, Zhou Z, Zhou Y, Wu X, et al
   Development and internal validation of a prediction model of prostate cancer on initial transperineal template-guided prostate biopsy.
   BMC Urol. 2021;21:68.
   PubMed         Abstract available
   
   

   
   Br J Radiol

9. HE X, Xiong H, Zhang H, Liu X, et al
   Value of MRI texture analysis for predicting new Gleason grade group.
   Br J Radiol. 2021 Mar 11:20210005. doi: 10.1259/bjr.20210005.
   PubMed         Abstract available
   
   

   
   Cancer

10. BUTLER SS, Mahal BA, Moslehi JJ, Nohria A, et al
    Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
    Cancer. 2021 Apr 27. doi: 10.1002/cncr.33486.
    PubMed         Abstract available
    
    

    
    Cancer Res

11. STROBL MAR, West J, Viossat Y, Damaghi M, et al
    Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.
    Cancer Res. 2021;81:1135-1147.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

12. TRUE LD, Chen DL
    How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer?
    Clin Cancer Res. 2021 Apr 23. pii: 1078-0432.CCR-21-0749.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

13. NABID A, Carrier N, Vigneault E, Van Nguyen T, et al
    OPTIMIZING TREATMENT IN INTERMEDIATE RISK PROSTATE CANCER: SECONDARY ANALYSIS OF A RANDOMIZED PHASE III TRIAL.
    Int J Radiat Oncol Biol Phys. 2021 Apr 23. pii: S0360-3016(21)00373.
    PubMed         Abstract available
    
    

    
    Int J Urol

14. KUSHWAHA B, Devi A, Maikhuri JP, Rajender S, et al
    Inflammation driven tumor-like signaling in prostatic epithelial cells by sexually transmitted Trichomonas vaginalis.
    Int J Urol. 2021;28:225-240.
    PubMed         Abstract available
    
    
15. FALAGARIO UG, Lantz A, Jambor I, Martini A, et al
    Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
    Int J Urol. 2021;28:47-52.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

16. HOCHT S, Mason M, Wiegel T
    Timing of ADT in Radiotherapy of Prostate Cancer.
    J Clin Oncol. 2021 Apr 29:JCO2100032. doi: 10.1200/JCO.21.00032.
    PubMed        
    
    
17. CHI KN, Chowdhury S, Bjartell A, Chung BH, et al
    Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    J Clin Oncol. 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
    PubMed         Abstract available
    
    

    
    J Nucl Med

18. RITT P, Jobic C, Beck M, Schmidkonz C, et al
    Dissimilar DNA Damage to Blood Lymphocytes After (177)Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2021;62:379-385.
    PubMed         Abstract available
    
    
19. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
    PubMed         Abstract available
    
    
20. OLDE HEUVEL J, de Wit-van der Veen BJ, van der Poel HG, van Leeuwen PJ, et al
    Cerenkov Luminescence Imaging in prostate cancer: not the only light that shines.
    J Nucl Med. 2021 Apr 30. pii: jnumed.120.260034. doi: 10.2967/jnumed.120.260034.
    PubMed         Abstract available
    
    
21. FENDLER WP, Farolfi A
    REPLY: The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
    J Nucl Med. 2021 Apr 30. pii: jnumed.121.262271. doi: 10.2967/jnumed.121.262271.
    PubMed        
    
    

    
    J Urol

22. RAJWA P, Mori K, Huebner NA, Martin DT, et al
    The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2021 Apr 27:101097JU0000000000001821. doi: 10.1097/JU.0000000000001821.
    PubMed         Abstract available
    
    
23. FAN L, Fei X, Zhu Y, Chi C, et al
    Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819.
    PubMed         Abstract available
    
    
24. LEYH-BANNURAH SR, Liakos N, Oelke M, Wagner C, et al
    Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.
    J Urol. 2021 Apr 27:101097JU0000000000001776. doi: 10.1097/JU.0000000000001776.
    PubMed         Abstract available
    
    
25. CHIN JL, Lavi A, Metcalfe MJ, Siddiqui K, et al
    Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.
    J Urol. 2021 Apr 28:101097JU0000000000001831. doi: 10.1097/JU.0000000000001831.
    PubMed         Abstract available
    
    
26. RAMAN AG, Sarma KV, Raman SS, Priester AM, et al
    Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
    J Urol. 2021 Apr 28:101097JU0000000000001832. doi: 10.1097/JU.0000000000001832.
    PubMed         Abstract available
    
    

    
    Magn Reson Imaging

27. BOSCHHEIDGEN M, Schimmoller L, Kasprowski L, Abrar D, et al
    Arterial spin labelling as a gadolinium-free alternative in the detection of prostate cancer.
    Magn Reson Imaging. 2021 Apr 24. pii: S0730-725X(21)00068.
    PubMed         Abstract available
    
    

    
    PLoS One

28. CHUNG JW, Kim HT, Ha YS, Lee EH, et al
    Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
    PLoS One. 2021;16:e0250254.
    PubMed         Abstract available
    
    

    
    Prostate

29. TAN B, Chen X, Fan Y, Yang Y, et al
    STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
    Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
    PubMed         Abstract available
    
    
30. BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
    (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
    PubMed         Abstract available
    
    
31. QU F, Gu Y, Xue M, He M, et al
    Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
    PubMed         Abstract available
    
    
32. HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
    Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
    PubMed         Abstract available
    
    
33. BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
    Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
    PubMed         Abstract available
    
    
34. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
    PubMed         Abstract available
    
    

    
    Radiology

35. LI M, Guo J, Hu P, Jiang H, et al
    Tomoelastography Based on Multifrequency MR Elastography for Prostate Cancer Detection: Comparison with Multiparametric MRI.
    Radiology. 2021;299:E259.
    PubMed        
    
    
36. GHAI S, Finelli A, Corr K, Chan R, et al
    MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial.
    Radiology. 2021;299:E258.
    PubMed        
    
    
37. BAZARGANI S, Bandyk M, Balaji KC
    Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: What about the Negatives?
    Radiology. 2020 Nov 3:202870. doi: 10.1148/radiol.2020202870.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: